Skip to main content
OpenTrials
Completed

NCT Number: NCT06355453

Evaluation of the Goldcrest Patch Performance

The Novii Patch is an accessory to the Novii+ Pod that connects directly to the Novii+ Pod and contains the surface electrodes that attach to the abdomen.

The primary objective is to collect Data on Skin Integrity and Patch Adhesion Quality From the Patch After 18 Hours of Wear. The secondary objective is to evaluate fetal monitoring on adult pregnant females greater than 32 weeks gestation and non-pregnant females to collect data on electrical fetal, maternal, and uterine activity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

22 year–70 year

Sex eligibility

Female

Study type

Observational

Primary location

GE HealthCare Research Park

Wauwatosa, Wisconsin, 53188, United States

About this study

The primary objective is to collect Data on Skin Integrity and Patch Adhesion Quality From the Patch After 18 Hours of Wear. The secondary objective is to evaluate fetal monitoring on adult pregnant females greater than 32 weeks gestation and non-pregnant females to collect data on electrical fetal, maternal, and uterine activity.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for all Subjects:

  • Adult Females, 22 to 70 years of age.
  • Must be able to read and speak English.
  • Able and willing to provide written informed consent.

Inclusion criteria

that apply to the pregnant person arm only:

  • Pregnancy of greater than or equal to 32.0 weeks gestation per self-report.

Exclusion criteria

  • Skin irregularities or other characteristic (such as scars, moles) on abdominal area that could interfere with completion of study procedures or identify a subject;
  • Subjects who have implantable devices such as Transcutaneous Electrical Nerve Stimulation (TENS) machines, Cardiac Pacemakers or Cardiac Defibrillators
  • Subjects expected to be at risk from participation for any reason, such as those with known allergy or sensitivity to adhesive materials that may be used in the study, such as silicone;
  • Subjects over the age of 70;
  • Unable to read or speak English language
  • Direct employees or contractors of GE HealthCare, or any company that makes fetal monitoring devices.

Exclusion criteria

that apply to specific arms only:

  • Non-Pregnant Arm: Subjects who are currently pregnant, or unsure of pregnancy status per self-report;
  • Pregnant Arm: Multiple gestation pregnancy or those self-reported to have been diagnosed as high risk by a provider (e.g., pre-eclampsia, gestational hypertension, being followed by a perinatologist).

Treatment and study plan

Goldcrest Patch and Three Patch Coupons

Device

Goldcrest patch and three patch coupons will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.

Goldcrest Patch and Novii Patch

Device

Goldcrest patch and Novii patch will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.

Primary outcomes

  1. Collection of Skin Integrity Quality

    Time frame: 18 hours

    To collect of skin integrity quality from a skin assessment scale the from the patch's after 18-hours of wear.

Secondary outcomes

  1. Collection of ECG Electrical Signal Data

    Time frame: 18 hours

    Collection of electrocardiogram (ECG) electrical signal data from the patch after 18 hours of wear.

  2. Collection of Subject Activity

    Time frame: 18 hours

    Collect of subject activity data utilizing a subject questionnaire during the 18 hours of wear.

  3. Collection of Patch Electrical Signal Data

    Time frame: 18 Hours

    Collection of electrical signal data from the patch's at the time of application for comparison to the electrical data after 18 hours of wear

Other outcomes

  1. Safety Analysis

    Time frame: 4 months

    Analysis of adverse events will be listed per subject, summarized with counts and percentages of events, and summarized with counts and percentages of subjects with events.

Sponsors and collaborators

Lead sponsor

GE Healthcare

Industry

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 9, 2024
Registry last updated
Jul 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.